Compare Gigacloud Technology Inc (GCT) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gigacloud Technology Inc vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Gigacloud Technology Inc trades at $57 (market cap $2.02B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 29.1× Gigacloud Technology Inc's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Gigacloud Technology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gigacloud Technology Inc for 21 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| GCT | TAK | |
|---|---|---|
Market Cap | $2.02B | $58.74B |
Volume | 1,020,985 | 3,110,994 |
Sector | Technology | Health |
52-Week High | $56.42 | $19.05 |
52-Week Low | $25.46 | $13.23 |
Typical Hold Time | 21 Days | 0 Days |
Enterprise Value | $2.14B | $86.65B |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GCT trades at $55.96, up 2.19% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with consistent earnings beats, 10.65% net margins, and 27.6% YoY revenue growth in Q2 2026. Recent news highlights institutional interest and European expansion driving optimism.
The outlook remains positive with 66.7% analyst buy ratings and a $32.50 consensus target, though RSI levels suggest potential near-term consolidation. Key risks include insider selling activity and market volatility, but strong cash flow generation and disciplined expansion support long-term growth prospects.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
